We have highlighted the need to harness real-world data to understand the impact of CFTR modulator treatment on allergic and non-allergic Aspergillus disease in CF, and to further evaluate the optimum management strategies of Aspergillus to ultimately lead to improved patient outcomes. The gene discussed is CFTR; the disease is cystic fibrosis.